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Myelin protein zero (MPZ) is a major component of compact myelin in peripheral
nerves. Mutations in MPZ have been associated with different Charcot–Marie–Tooth
disease (CMT) phenotypes (CMT1B, CMT2I/J, CMTDI), Dejerine–Sottas syndrome, and
congenital hypomyelination neuropathy. Here, we report phenotypic variability in a four-
generation Chinese family with the MPZ mutation Asp121Asn. Genetic testing was
performed on nine family members and 200 controls. Clinical, electrophysiological
and skeletal muscle MRI assessments were available for review in six family
members. A novel heterozygous missense mutation, Asp121Asn, was observed in
five affected members of the family. Unaffected relatives and 200 normal controls
were without the mutation. Four of the affected members of the family displayed
late-onset, predominantly axonal sensory and motor neuropathy, pupil abnormalities,
and progressive sensorineural hearing loss. One young affected member presented
with Argyll–Robertson pupils and diminished deep tendon reflexes in the lower limbs.
The MPZ mutation Asp121Asn may be associated with late-onset axonal neuropathy,
early onset hearing loss and pupil abnormalities. Our report expands the number and
phenotypic spectrum of MPZ mutations.
Keywords: Charcot–Marie–Tooth disease, hearing loss, myelin protein zero, novel mutation, pupil abnormalities
INTRODUCTION
Charcot–Marie–Tooth disease (CMT) is a genetically heterogeneous group of disorders affecting
the peripheral nervous system. The number of disease genes identified in CMT has expanded
rapidly over the past few decades (Rossor et al., 2013). Mutations in the myelin protein zero (MPZ)
gene are one of the most frequent causes of CMT. To date, 190 different mutations have been
documented1. In this report, we present five patients from a four-generation Chinese family who
contain a novel missense mutation in MPZ.
1http://www.hgmd.org/
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PATIENTS AND METHODS
Patients
The family included 7 affected and 10 unaffected members over
four generations (Figure 1A). This study was approved by the
ethical committees of the China-Japan Friendship Hospital and
the Peking University Third Hospital. Written informed consent
was obtained from all participants.
The proband (III-5), a 45-year-old man, presented with a 9-
year history of progressive difficulty in walking coupled with
hearing loss. At 36 years of age, he developed numbness and
weakness in his legs. He also noticed a progressive bilateral
hearing loss with tinnitus. Hand-grip weakness and numbness
became evident 3 years after onset. The disease progressed over
the next few years, resulting in marked wasting of the calf
muscles and foot drop. He required hearing aids at the age of
45. Neurological examination indicated muscle weakness and
atrophy in the distal legs and hands. The muscle strength of the
anterior tibial and gastrocnemius muscles was 3 of 5 (Medical
Research Council [MRC] scale). The muscle strength of the foot
and ankle flexor–extensor muscles was 0 of 5, and pes cavus and
steppage gait were present. A score of 4 of 5 was recorded for
the finger abductor and adductor muscles. Deep tendon reflexes
were absent in the lower limbs and diminished in the upper
limbs. Pyramidal tract signs were not observed. There was mild
reduction of perception to touch, pain and temperature in glove-
stock distribution and moderate reduction of vibration sense in
the feet. The pupils were asymmetric (left, 4 mm; right, 2 mm)
with a slow response for the light reflex and accommodation
reaction.
Patient (IV-7), the proband’s 24-year-old son, did not
complain of paresthesia or weakness of his limbs. He only
noticed that he was slightly unsteady when walking on his
heels and toes. He denied hearing and vision problems. On
examination, positive signs included pupil abnormalities (pupils
had a symmetrical but irregular size of 2 mm and were
FIGURE 1 | (A) Family tree of a Chinese family of Asian descent affected by peripheral neuropathy, pupil abnormalities, and progressive sensorineural hearing loss.
The family included 7 affected and 10 unaffected members over four generations. The proband is member III-5. The other family members, II-1, II-3 III-1-4, III-6, and
IV-7, were examined clinically or electrophysiologically and received genetic testing. (B) A novel heterozygous missense mutation c.361G>A was identified in MPZ
exon 3, which caused the Asp121Asn substitution in the extracellular domain. (C)The position of the mutation is highly conserved in vertebrates, juxtaposed with
known mutations, and located within the critical disulfide bonding domain responsible for the adhesive properties of MPZ.
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unresponsive to light but exhibited normal constriction on
convergence) and diminished deep tendon reflexes in the lower
limbs. The muscle strength of the limbs was 5 of 5 on the MRC
scale. Sensory examinations were unremarkable.
Patient (II-2), the proband’s mother, died at the age of 66.
She suffered from hearing loss at age 38 and then developed
gait difficulties with decreased sensation in both of her lower
limbs at the age of 40. She became completely deaf at the age of
50. She also had a history of recurrent coughing spasms. These
episodes would typically last for 20–30 min and end in vomiting
or syncope. The deceased mother also displayed gait disturbances
and hearing impairment.
Patients (III-2, III-3, III-4) were affected between the ages of
36 and 40 with symptoms comparable to those of the proband
(Table 1). All of the children of these patients are currently
asymptomatic.
Genetic Analysis
Duplication of the fragment that contains PMP22 was performed
with multiplex ligation-dependent probe amplification (SALSA
MLPA kit P033, MRC-Holland). The coding and splicing of the
site-flanking regions of PMP22, MFN2, GJB1, and MPZ were
PCR amplified with intronic primers and directly sequenced
using Applera BigDye version 3.1 (Applied Biosystems, Foster
City, CA, USA) and the automated sequencer ABI 3730XL
(Applied Biosystems). The amplicon sequences were aligned by
SeqMan Pro to the published human gene sequences in the
NCBI database2 with 7.1.0 (DNASTAR Inc., Madison, WI, USA).
All nucleotide differences were compared to dbSNP3 and to the
human genetic mutation databases IPNMDB4 and HGVS5. The
in silico pathogenicity prediction tools Provean6, PolyPhen7 and
Mutation Taster8 were used to further validate the mutations.
RESULTS
Clinical Findings
All patients presented with pes cavus, distal sensory loss,
and gradually progressive weakness of the lower and upper
extremities, and they developed bilateral hearing loss. The
proband plus patients III-2-4 exhibited pupillary abnormalities.
Patient II-2 had a record of coughing spasms, and the autonomic
nervous system may have been involved. Patient IV-7 was
asymptomatic, and examination only identified diminished deep
tendon reflexes in the lower limbs and Argyll–Robertson pupils.
Patients III-2, III-5, and IV-7 participated in
electrophysiological tests (Table 2). Patient III-2 and proband
III-5 displayed a predominantly axonal neuropathy with only
mild myelin changes and marked abnormalities in the lower
2http://www.ncbi.nlm.nih.gov
3http://www.ncbi.nlm.nih.gov/projects/SNP
4http://www.molgen.ua.ac.be/CMTMutations/
5http://www.hgvs.org
6http://provean.jcvi.org/index.php
7http://genetics.bwh.harvard.edu/pph2/index.shtml
8http://www.mutationtaster.org/
limb motor nerves. Proband III-5 exhibited minor slowing in
motor conduction velocity and decreased compound motor
action potentials (CMAP) in the median nerve. The amplitudes
of sensory nerve action potentials (SNAP) were predominantly
reduced with mild slowing in the sensory conduction velocities
of the median and ulnar nerves. The lower limb nerves
exhibited severely decreased or absent CMAP and SNAP with
slowing nerve conduction velocities. Patient III-2 showed
results similar to those of the proband. The brainstem auditory
evoked potentials (BAEP) of Patients III-2 and III-5 showed
evidence of peripheral lesions. Audiometry for Patients III-2
and III-5 indicated symmetric sensorineural hearing loss in
the 30–50 dB hearing level (HL) at moderate frequencies and
severe hearing loss in the 50–80 dB HL at high frequencies.
All electrophysiological tests for Patient IV-7 (at age 24) were
preserved.
Skeletal muscle MRI of the lower limbs was performed
on proband III-5 and his son IV-7 (Supplemental Figure 1).
Proband III-5 displayed extensive and symmetric fatty atrophy
of the four lower leg muscle compartments, particularly in the
anterolateral compartments and gastrocnemius muscles. Fatty
infiltration was classified as stage IV. Patient IV-7 exhibited subtle
and symmetric fatty infiltration of the soleus and gastrocnemius
muscles. Fatty infiltration was classified as between stages 0 and
I. The MRI images of the proband and his son indicated that
fatty infiltration was related to disease duration. These findings
are similar to the reported features of axonal CMT2 neuropathy
(Gallardo et al., 2009).
Genetic Analysis
Molecular analysis of PMP22 ruled out the presence of a
duplication or deletion. Direct sequence analysis of PMP22, GJB-
1, MFN2, and MPZ was performed for proband III-5. A novel
heterozygous missense mutation c.361G>A was identified in
MPZ exon 3 (Figure 1B), which caused the Asp121Asn
substitution in the extracellular domain. This mutation was
subsequently observed in all of the affected patients who were
examined but not in the four unaffected relatives (II-1, II-3, III-
1, III-6). Direct testing of asymptomatic children IV-3-6 was
not authorized by their parents. The nucleotide substitution was
absent in 200 control chromosomes from unrelated Chinese
individuals.
Provean (deleterious, p = −2.99), Mutation Taster (disease-
causing probability score = 1) and PolyPhen2 (probably
damaging, PSIC: 0.995) all predicted that the mutation was
damaging. This amino acid is highly conserved in vertebrates,
juxtaposed with known mutations and found within the critical
disulfide bonding domain responsible for the adhesive properties
of MPZ (Figure 1C).
DISCUSSION
Patients with MPZ mutations exhibit a wide range of phenotypic
variability beyond the peripheral nervous system, including
pupillary abnormalities, hearing loss, diaphragmatic weakness or
chronic cough, restless-leg-like symptoms and multiple sclerosis
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(De Jonghe et al., 1999; Baloh et al., 2004; Kilfoyle et al., 2006).
Such variability may be related to dosage of the MPZ protein
or the position and nature of the MPZ mutation. In this report,
we described a large Chinese family with late-onset axonal
neuropathy, pupil abnormalities, and hearing loss associated with
a novel mutation in MPZ.
In this family, similar symptoms began around the fourth
decade of life. The patients’ (II-2, III-2-5) symptoms began with
distally accentuated sensory and motor symptoms in limbs, or
hearing impairment, followed by the appearance and subsequent
development of lesion-associated symptoms. Patient II-2 also had
a history of recurrent coughing spasms. Similar cases have been
TABLE 1 | Clinical features in individuals with genetically confirmed neuropathy.
Pedigree Sex Onset age
(years)
Clinical features Muscle strength Reflexes Hearing loss
age (years)
UL LL
II-2 F 40 Gait difficulties, hypoesthesia of
distal lower limbs, cough
spasms
NA NA NA 38
III-2 F 38 Weakness and numbness of
distal lower limbs, pes cavus,
pupil abnormalities
4 0–3 Absent in ankle and knee 37
III-3 F 37 Distal hypoesthesia and
paresthesia, distal weakness,
pes cavus, Adie’s pupil
4 0–2 Diminished in the upper limbs
and absent in the lower limbs
38
III-4 F 36 Bilateral foot drop and distal
dysesthesia, pes cavus, pupil
abnormalities
5 0–2 Absent in ankle and knee 36
III-5 M 36 Distal weakness and
paresthesia, pes cavus, Adie’s
pupil
4 0–3 Diminished in the upper limbs
and absent in the lower limbs
36
IV-7 M N Argyll–Robertson pupils 5 5 Diminished in the lower limbs N
F, female; M, male; UL, upper limbs; LL, lower limbs; N, no finding; NA, not available for clinical studies.
TABLE 2 | Electrophysiological features in three affected members of the family.
Proband III-5 (45 years) Patient III-2 (50 years) Patient IV-7 (24 years)
Nerve MCV, m/s DL, ms CMAP, mV MCV, m/s DL, ms CMAP, mV MCV, m/s DL, ms CMAP, mV
Median
E-W 46.5↓ 8.3 4.21↓ 55.1 7.1 14.4 57.8 5.8 15.4
W-APB 4↓ 3.71↓ 3.2 15.7 2.6 16.9
Ulnar
E-W 53 6.5 6.9 53.8 6.4 8.9 62.5 5.3 13.1
W-ADM 2.67 6.4 2.5 7.1 2.1 13.6
Tibial
K-A 37.3↓ 12.4 0.16↓↓ 33.9↓ 15.6 0.49↓↓ 46.4 10.9 4.8
A-FHB 4.5 0.22↓↓ 4.9 2.26↓ 3.8 7.1
Peroneal
K-A NR NR NR ND ND
A-EDB NR NR ND ND
Nerve SCV, m/s SNAP, µV SCV, m/s SNAP, µV SCV, m/s SNAP, µV
Median
IIIF-W 35.5↓ 2.6↓↓ 50 2.9↓↓ 59.2 5.8
Ulnar
VF-W 37.1↓ 1.6↓↓ 40.7 2.4↓↓ 54.7 5.3
Sural
A-sural NR NR NR NR 50.1 4
A, ankle; ADM, abductor digiti minimi; APB, abductor pollicis brevis; CMAP, compound muscle action potential; DL, distal latency; E, elbow; EDB, extensor digitorum
brevis; FHB, flexor hallucis brevis; III F, third finger; K, knee; MCV, motor conduction velocity; SCV, sensory conduction velocity; SNAP, sensory nerve action potential; V
F, fifth finger; W, wrist; NR, no response; ND, not performed. ↓↓, remarkable decrease or reduction. ↓, mild decrease or reduction.
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reported that are associated with the Thr124Met mutation in
MPZ (Baloh et al., 2004). Patient IV-7 was asymptomatic at age
24. Our findings indicate that until adulthood, his disease may
remain quiescent with only unnoticeable pupillary abnormalities
and early selective length-dependent hyporeflexia. As reported
previously, abnormal or abolished pupillary reflex may be the
first sign of CMT disease associated with MPZ mutation,
as asymptomatic carriers may present pupillary abnormalities
before they reach the age of onset (De Jonghe et al., 1999; Misu
et al., 2000). Furthermore, a previous case reported that the
Thr124Met mutation in MPZ results in the early involvement
of the autonomic nervous system and the late involvement
of the somatic peripheral nervous system (Baloh et al., 2004).
Our study suggests that MPZ may also be involved in the
autonomic system, which includes unmyelinated post-ganglionic
sympathetic and parasympathetic axons. The pupils exhibited a
slow but preserved miosis associated with accommodative effort,
suggesting damage to the post-ganglionic parasympathetic fibers
(Murphy et al., 2011). Similar pupillary dysfunction resulting
in a lack of response to light but a retained response to
accommodation was reported in patients with the Thr124Met,
His81Tyr, and Val113Phe MPZ mutations (Bienfait et al., 2002).
Because tonic pupils are more often observed in axonal rather
than demyelinating forms of CMT (Hattori et al., 2003), MPZ
must be critical for the maintenance of axonal function in
addition to its role as a structural protein in myelin.
Hearing impairment appears to be an additional feature
of late-onset CMT2 disease. The documented MPZ mutations
associated with variable degrees of hearing loss are Thr124Met,
Asp75Val, Glu97Val, Tyr145Ser, Pro105Thr, and His39Pro (De
Jonghe et al., 1999; Misu et al., 2000; Starr et al., 2003; Kilfoyle
et al., 2006; Kabzin´ska et al., 2007). In this study, BAEP and
audiometry findings indicated sensorineural deafness in the
affected family numbers with a novel Asp121Asn mutation.
Based on a recent study investigating the Tyr145Ser mutation
in MPZ, in sural and auditory/vestibular nerves, the pathological
findings indicated a loss of large myelinated fibers and thinning
of the myelin sheath of the remaining axons, consistent with a
primary axonal disorder with incomplete remyelination (Starr
et al., 2003). Price et al. (1993) divided the denervated muscles
for the lower legs into “P-type” (peroneal) and “T-type” (tibial)
depending on the predominant muscles affected by neuropathy.
The family in the present study displayed a characteristic pattern
of “partial T-type” muscles abnormalities. The observed normal
thigh musculature versus distally accentuated fatty infiltration of
the lower leg muscle bellies in proband III-5 also concurs with
length-dependent axonopathy.
Most MPZ mutations are located within the extracellular
or transmembrane domain of the mature MPZ protein. In
this report, the missense mutation identified in exon 3 of
MPZ results in a conservative amino acid exchange at position
121 from aspartic acid to asparagine, which corresponds to
an extracellular domain of MPZ responsible for its adhesive
properties. We implicate this mutation as underlying the CMT
phenotypes observed in this family for the following reasons: (1)
All affected members contained the mutation, whereas unaffected
members did not. (2) The mutation was not observed in 200
healthy controls without neuropathy. (3) Provean, Mutation
Taster, and PolyPhen2 all predicted that the mutation was likely
damaging. (4) The amino acid is highly conserved in vertebrates;
is juxtaposed with known mutations (reported as Tyr119Cys
[Senderek et al., 2000]), such as Asn122Ser; and is located in the
critical disulfide bonding domain (between Cys-50 and Cys-127)
responsible for the adhesive properties of the protein. (5) Lastly,
the mutation occurs in an extracellular MPZ domain, producing
a polarity variation that may consequently affect the hydrogen
bonds responsible for the correct folding and dimerization of the
protein (Supplemental Figure 2).
CONCLUSION
The identification of a novel mutation in MPZ in this family
expands our knowledge of the genetics of CMT2. The Asp121Asn
mutation identified in this study together with the detailed
clinical description of the affected family members broadens the
phenotypic spectrum of mutations in the extracellular domain of
MPZ and emphasizes the influence of other modulatory factors
in the expression of disease pathology.
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SUPPLEMENTAL FIGURE 1 | Axial and coronal T1-weighted images of the
lower limbs. Proband III-5 (C, F) exhibited fatty infiltration, including
massive fatty atrophy of the anterolateral compartments and
gastrocnemius muscles. His son, IV-7 (B, E) displayed subtle and symmetric
fatty infiltration of the soleus and gastrocnemius muscles. (A) and (D) depict the
normal appearance of the lower leg musculature of a healthy control.
SUPPLEMENTAL FIGURE 2 | The Asp121Asn mutation is predicted to
change the protein structure by introducing a neutral-polar amino acid
from a polar charge. Asp121 has acidic features and acts as a hydrogen bond
acceptor because of its side chain carboxylic function. Conversely, Asn121 is
basic and may act both as a hydrogen bond acceptor and donor based on its
side-chain amidic nitrogen. Thus, Asp121Asn may affect the hydrogen bonds
responsible for the folding and dimerization of the α-helix structure. However,
Asp121Asn does not dramatically change the tertiary protein structure, which
results in late-onset instead of early onset axonal neuropathy.
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